What type of targeted anti-cancer drugs does erdafitinib belong to?

Erdafitinib (Erdafitinib) is a type of selective FGFR (fibroblast growth factor receptor) inhibitor. Its specific mechanism of action is to inhibit the tyrosine kinase activity of four receptors: FGFR1, FGFR2, FGFR3 and FGFR4, thereby blocking abnormally activated signaling pathways and inhibiting the proliferation, differentiation and angiogenesis of tumor cells. This drug works in the form of a small molecule tyrosine kinase inhibitor (TKI) and is a new generation of precision medicine with great research value in the molecular targeted therapy system.

The FGFR signaling pathway plays an important role in normal cell development, but in some malignant tumors, this pathway is continuously activated due to gene mutation, amplification or fusion, becoming a key driver of cancer cell growth. Especially in tumors such as urothelial cancer (bladder cancer), cholangiocarcinoma, and liver cancer, abnormal expression or structural changes of FGFR2 and FGFR3 are considered potential targets. Erdafitinib achieves the purpose of blocking tumor development by inhibiting these abnormal signaling activities.

From the clinical positioning point of view, erdafitinib is a highly precise treatment drug and is not a broad-spectrum anti-cancer drug. It is mainly used for patients who have been confirmed by molecular testing to have FGFR mutations or fusions. This concept of "targeted matching therapy" significantly improves the effectiveness of treatment and patient tolerance. Compared with traditional chemotherapy or radiotherapy, erdafitinib is more convenient to administer (it is an oral drug) and has demonstrated better disease control capabilities in some cases.

In addition, the research of erdafitinib is not limited to the field of bladder cancer. Research trials on other tumors with abnormal FGFR such as intrahepatic cholangiocarcinoma, glioblastoma and even breast cancer are being carried out in multiple centers around the world, which is expected to expand its scope of indications. With the increasing popularity of genetic testing in clinical practice, FGFR-targeted therapeutic drugs may be widely used in more cancer types in the future. As one of the representative varieties, the potential of erdafitinib cannot be underestimated.

Reference materials：https://www.balversa.com/